Kornimate/medical-research-clean huggingface dataset:
chiropractic and acupressure for headaches

Conditions: Cervicogenic Headache; Tension-type Headache; Migraine Headache

Summary: this study will investigate the effect of chiropractic treatment with and without the use of an acupressure pillow for cervical headaches. subjects will be randomly allocated to groups with and without the pillow and will be followed for five weeks. the primary outcome measure will be headache frequency. the investigators predict that the group using the pillow on a daily basis will demonstrate significantly greater decrease in headache frequency over a 5-week interval.


Eligibility criteria:
inclusion criteria: * males and females * ages 21-60 * recurrent headaches * sub-occipital tenderness * a minimum of 4 headaches per month exclusion criteria: * migraine with aura * sinus headache * any other organic pathology * any contraindications to cervical manipulation

Keywords: headache chiropractic manipulation acupressure self-care
an extension study of rpc1063 as therapy for moderate to severe ulcerative colitis

Conditions: Ulcerative Colitis

Summary: the purpose of this study is to evaluate the long-term safety and efficacy of rpc1063 in participants with moderately to severely active ulcerative colitis. only those participants who have previously participated in a trial of rpc1063, being either rpc01-3101 or completed at least 1 year of the open-label period of rpc01-202 will be eligible.

this is an extension study trial. eligible participants from the rpc01-3101 and rpc01-202 trials were able to roll-over in this trial to receive study medication until march 2023 or until the sponsor discontinues the development program, whichever comes first.

Eligibility criteria:
for more information regarding bristol-myers squibb clinical trial participation, please visit: www.bmsstudyconnect.com inclusion criteria: • previously participated in a trial of rpc1063 and meets the criteria for participation in the open-label extension as outlined in the prior trial exclusion criteria: * receiving treatment with breast cancer resistance protein inhibitors * clinically relevant cardiovascular conditions * liver function impairment other protocol-defined inclusion/exclusion criteria apply
study of clinical response to acute metformin by leveraging evaluations during a mixed meal tolerance test for exploring glycemia and genetics

Conditions: Genetics; Metabolism; Type 2 Diabetes

Summary: the purpose of this research study is to examine whether specific genes (e.g. slc16a11) affect how human beings respond to food and a medication that is commonly used to treat type 2 diabetes. the food the investigators will be studying is specially prepared to contain protein, carbohydrate, and fat. the drug the investigators are studying is metformin. the investigators hypothesize that physiological responses to the meal and to the medication will differ between carriers and non-carriers of genes associated with type 2 diabetes.


Eligibility criteria:
inclusion criteria: * adult males or non-pregnant females * age 18-79 * able and willing to give consent relevant to genetic investigation exclusion criteria: * women who are pregnant, nursing, or at risk of becoming pregnant * currently taking any medications used for the treatment of diabetes * history of liver disease and/or aspartate aminotransferase (ast) or alanine aminotransferase (alt) more than 3 times upper limit of normal (uln) * estimated glomerular filtration rate (egfr) \< 60 ml/min/1.73 m2 as calculated by the modification of diet in renal disease equation * currently taking or intending to take during the study duration any medication known to affect glycemic parameters, such as glucocorticoids, growth hormone, or fluoroquinolones * contraindications to safe use of metformin, including planned radiologic or angiographic study requiring contrast within one week of the study completion * planned changes to any prescribed medications, specifically diuretics, during study enrollment * participation in any other interventional study during the study duration * conditions causing intestinal malabsorption, including celiac disease or a history of intestinal or gastric bypass surgery * dietary restrictions that would prevent consumption of a mmtt * objection or inability to take metformin
impella pump return study to analyze deposits and biomaterial in used pumps

Conditions: Heart Failure

Summary: analysis of cell and protein deposits on the impella heart pump.

the impella heart pump supports patients in cardiogenic shock for various reasons and has passed safety and biocompatibility evaluations. the planned investigation aims to further analyze cell and protein adhesion on these pumps and the effects of their prolonged use, especially in scenarios like bridge-to-transplant, recognizing preclinical testing limitations.

Eligibility criteria:
inclusion criteria: * patients with impella 5.5 therapy and duration of support for ≥ 25 days or patients with impella cp therapy and duration of support for \> 4 days * use of sodium bicarbonate as a purge additive as permitted by the ifu exclusion criteria: * age \< 18 years
analysis of inhaled corticoid prescriptions in general medicine

Conditions: Asthma; Chronic Obstructive Pulmonary Disease

Summary: chronic obstructive pulmonary disease (copd) and asthma are frequent and disabling pathologies. the general practitioner is often at the front line vis-a-vis screening, diagnosis and treatment of these pathologies. there are currently many treatments available, in particular inhaled corticosteroids, and although the recommendations for management appear to be well codified in theory, the adaptation of drug therapy remains complex in general practice. the prescription of inhaled corticosteroids, often initiated during a general medicine consultation, is not simple. the aim of this study is to analyze the relevance of the prescription of inhaled corticosteroids in primary care and to identify the criteria necessary for the prescription of inhaled corticosteroids available in general practice. the main objective of our study is to evaluate the rate of consultations where all the elements required for guiding the prescription of an inhaled corticoid are available. the secondary objectives are: * identify other factors associated with decision-making * identify the causes of inhaled corticosteroid stopping (de-prescription)


Eligibility criteria:
inclusion criteria: * patient with short-term inhaled corticosteroid therapy * informed and not opposed to participate in this research exclusion criteria: * patient under judicial or legal protection * adults under any kind of guardianship -
promoting behavioral change for oral health in american indian mothers and children

Conditions: Early Childhood Dental Caries

Summary: a program of motivational interviewing plus enhanced community services in prevention of early childhood caries vs. enhanced community services alone for american indian mothers and their children will reduce the childrens' decayed, missing, and filled tooth surfaces measure over a 3-year period.

this is a randomized, controlled clinical trial. six hundred mothers and their children will be randomized over a 2-year period to motivational interviewing (mi) plus enhanced community services vs. enhanced community services alone in equal numbers in the 2 groups. the mi sessions will involve home visits concentrating on the mitigation of behavioral risk factors for early childhood caries (ecc), shortly after childbirth and at 6, 12, and 18 months. the enhanced community services will involve development of culturally appropriate messages related to the mitigation of risk factors for ecc through public announcements and simple brochures. the primary outcome measure will be decayed, missing, and filled tooth surfaces (dmfs) of the children at ages 1, 2, and 3. secondary outcomes will include children's ds, % with dmfs and ds \>0, mother's dental knowledge, attitudes, and behaviors, caries patterns, and costs.

Eligibility criteria:
inclusion criteria: * be american indian, as defined by the tribe * be mothers or caregivers of newborn children * at least 15-44 years of age (minors who are 15-17 years of age must get consent from a parent or legal guardian according to tribal, state, and ihs rules and regulations) * able to read, understand, and sign a consent form/assent form, * be willing and able to follow study procedures and instructions. exclusion criteria: * no exclusion criteria. although expected to be rare, if the father is a sole caregiver, he and his child will be eligible for the study.
effectiveness of a 6-week specific rehabilitation program on walking capacity in patients with lumbar spinal stenosis

Conditions: Spinal Stenosis

Summary: the aim of this study is to determine the effectiveness of a 6-week specific rehabilitation program combining education and exercises on walking capacity in patients with lss causing nc. the intervention group will receive standardized education and specific exercises while the control group will only receive standardized education. the program in both groups will last for 6 weeks with 4 evaluation timepoints (baseline, week 2, week 4 and post-intervention assessment). the primary outcomes will be walking capacity measured with the self-paced walking test and the secondary outcomes will be back and leg pain intensity, lss-related disability, self-efficacy, level of physical activity, anxiety and depression, physical activity level, gait pattern characteristics, balance, and global perceived change.


Eligibility criteria:
inclusion criteria: * being at least 50 years old * having a degenerative central lss alone or in combination with other lss types (e.g. foraminal, lateral) and/or a spondylolisthesis affecting one or multiple vertebral levels, confirmed by clinical history, physical examination and proper imaging * having nc associated with lss * being able to speak and understand french * being willing to attend 3 intervention sessions per week * with a duration of signs and symptoms of at least 3 months * (7) being able to walk at least 20 meters without walking aid, but not being able to walk continuously for 30 minutes * being able to provide informed written consent. exclusion criteria: * congenital lss, * symptomatic osteoarthritis (hip or knee) causing limited walking capacity * neurological disease affecting walking capacity such as parkinson * uncontrolled diabetes * heart failure * intermittent claudication of vascular origin * impaired cognitive capacity * back or lower extremities surgery in the past 3 months

Keywords: spinal stenosis neurogenic claudication walking capacity exercises education gait pattern characteristics
assessment of posture, balance, gait disorders in patients with fibromyalgia

Conditions: Fibromyalgia; Chronic Pain

Summary: the study aims to determine the posture, balance and gait disorders objectively in patients with fibromyalgia (fm) and to investigate their relationships with disease-related parameters.

after being informed about study and potential risks, all participants giving written informed consent will undergo screening period determine eligibility for study entry. the participants who met the eligibility recruitments will get into the assessment. the study will include 100 participants aged between 18-65 years and without any disease or orthopedic disorder that can cause posture, balance and gait disorders: 50 female patients who met the acr (american college of rheumatology) 2016 fm diagnostic criteria and 50 pain-free females. researcher will record sociodemographic data of all participants and disease duration of patients with fm. the researcher will evaluate disease activity by fibromyalgia impact questionnaire, sleep quality by pittsburgh sleep quality index and fatigue severity by fatigue severity scale in fm group. in both groups the researcher will use; diers formetric 3d/4d video-rasterstereography (diers international gmbh, schlangenbad, germany) device for the posture analyze, hur smartbalance btg4 system (hur labs, kokkola, finland) for postural balance control and limits of stability measurements, zebris fdm type 3 (zebris medical gmbh, germany) gait analysis system for measuring spatio-temporal gait parameters.

Eligibility criteria:
inclusion criteria: * being diagnosed with fibromyalgia according to acr 2016 diagnostic criteria * signing written informed consent to participate in the study exclusion criteria: * rheumatological, neurological and/or psychiatric diseases that may cause balance and gait disorders (cerebrovascular accident sequelae, parkinson's, myasthenia gravis, polyneuropathy, rheumatoid arthritis, ankylosing spondylitis, major depression) * other diseases that cause balance and other gait disorders (history of major trauma to the lower extremity, and/or orthosis users, those who have had spinal and/or lower extremity surgery) * orthopedic disorders that may cause limitation in joint range of motion and/or loss of motor muscle strength * those who cannot take commands due to cognitive dysfunction * vestibular and/or cerebellar disorders * abnormal ophthalmic/optometric disorder (vision disorders) * pregnancy * serious cardiac disease, malignancy and renal failure

Keywords: fibromyalgia posture postural stability balance gait
an observational study to assess change in disease activity and adverse events of rinvoq in adult participants with moderate to severe ulcerative colitis (uc) in japan

Conditions: Ulcerative Colitis

Summary: ulcerative colitis (uc) is an idiopathic, chronic, inflammatory disease affecting the colon. participants with uc have mucosal inflammation starting in the rectum that can extend continuously to proximal segments of the colon. this study will assess how safe and effective rinvoq is in treating adult participants with moderate to severe ulcerative colitis (uc). adverse events and change in disease activity will be assessed. rinvoq is a drug approved for the treatment of ulcerative colitis (uc). all study participants will receive rinvoq as prescribed by their study doctor in accordance with approved local label. approximately 300 adult participants will be enrolled in japan. participants will receive upadacitinib as prescribed by their physician according to their routine clinical practice and local label. participants will be followed for up to 60 weeks. there is expected to be no additional burden for participants in this trial. participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.


Eligibility criteria:
inclusion criteria: * participants diagnosed with moderately to severely active ulcerative colitis (uc). * participants who are within 14 days from the commencement of rinvoq treatment for uc. * participants who are administered the first dose of rinvoq for uc after approval for uc in japan. exclusion criteria: * participants currently participating in registrational clinical trial. * participants for whom rinvoq is contraindicated. * participants that have been previously exposed to rinvoq.

Keywords: ulcerative colitis uc rinvoq upadacitinib
effect of 0.1% pilocarpine mouthwash on xerostomia

Conditions: Xerostomia

Summary: the aim of this study is to evaluate the effect of 0.1% pilocarpine mouthwash on subjective dryness, minor salivary flow rates and unstimulated whole salivary flow rate in xerostomic patients.


Eligibility criteria:
inclusion criteria: * xerostomia for 3 months or more, and * adults aged 20 years and older. exclusion criteria: * acute asthma attack * acute iritis * narrow angle glaucoma * pilocarpine allergy * pregnancy * lactating women, and * person who was treating xerostomia with artificial saliva, pilocarpine, or etc.

Keywords: xerostomia pilocarpine mouthwash minor salivary gland secretion
evaluation of breathing, sleep and the effects of continuous positive airway pressure during wakefulness in children with heart failure

Conditions: Heart Failure

Summary: adult patients with heart failure (hf) have an increased work of breathing and are at increased risk for obstructive and/or central apnea during sleep. noninvasive continuous positive airway pressure (cpap) has proved its efficacy in decreasing the work of breathing and improving sleep-disordered breathing in these patients. the aim of the study is to analyze the work of breathing and objective and subjective sleep quality in children with hf and to evaluate the ability of noninvasive cpap to decrease the work of breathing and improve cardiac output during wakefulness.

the study starts with the measurement during wakefulness of * the breathing pattern and work of breathing * and cardiac function during 5 min after 10 min of stable and calm spontaneous breathing (sb) then the same measurement are made during 5 min after 10 min of stable and calm breathing during non-invasive cpap then a third measurement is made of * the breathing pattern and work of breathing * and cardiac function during 5 min after 10 min a stable and calm sb polysomnography is then performed during the following night during sb in order to assess objective sleep quality. subjective sleep quality is assessed on the following morning in children \> 6 years of age by validated sleep questionnaires.

Eligibility criteria:
inclusion criteria: * a child with hf and having: * dilated cardiomyopathy with an ejection fraction \<45% * univentricular congenital heart disease * left ventricular valvulopathy * age 8 months to 17 years * signed informed consent by the owner (s) of parental authority and investigator * patient affiliated to a social security scheme or entitled (excluding meas) * comparison of results depending on the status t21 / t21 not. exclusion criteria: * hf with use of inotropic drugs during the last 30 days. * contra indication to cpap or inability to maintain the airway or adequately remove phlegm, risk of aspiration of gastric contents, acute sinusitis or diagnosis of otitis media, epistaxis, hypotension. * associated pathology may be responsible alone an obstructive apnea (ent or maxillofacial malformation pathology, abnormalities of the upper airway, obesity with bmi z-score\> 2), a central apnea syndrome (chiari malformation), or alveolar hypoventilation (neuromuscular disease, cystic fibrosis or bronchopulmonary dysplasia).

Keywords: heart failure child work of breathing cardiac function sleep polysomnography cpap
pd1 antibody and lenalidomide as a treatment for ebv-hlh or caebv

Conditions: EBV Infection

Summary: the present study was a prospective one-arm clinical study, in which ebv-hlh/chronic active ebv infection patients were selected as the main subjects to evaluate the effect of pd-1 antibody and lenalidomide regimens on ebv-dna and safety.


Eligibility criteria:
inclusion criteria: 1. patients with caebv confirmed by 2016 revised world health organization classification. 2. if the patient has previously suffered caebv-hlh, the hlh should be in remission. 3. a woman of childbearing age must be determined not to be pregnant by a pregnancy test and is willing to take effective measures to prevent pregnancy during the trial period and ≥12 months after the last administration of the drug; all male subjects used contraceptive methods during the study period and ≥6 months after the last administration; 4. ages eligible for study: 1 year to 65 years. 5. sign the informed consent. exclusion criteria: 1. heart function above grade ii (nyha). 2. pregnancy or lactating women. 3. allergic to pd-1 antibody or lenalidomide. 4. active bleeding of the internal organs. 5. uncontrollable infection. 6. participate in other clinical research at the same time.
the effect of extracorporeal shock wave therapy after botulinum toxin type a injection for post-stroke spasticity

Conditions: Stroke; Hemiplegia, Spastic; Muscle Spasticity

Summary: there are few studies on whether botulinum toxin treatment and extracorporeal shock wave therapy are more effective than botulinum toxin alone treatment for post-stroke spasticity.

if the study results can be drawn that the group receiving extracorporeal shock wave therapy along with botulinum toxin treatment can increase the effect of botulinum toxin treatment and lengthen the treatment period compared to the group with botulinum toxin treatment only, it can be widely used as an auxiliary treatment for botulinum toxin treatment. this study was carried out with the expectation that it would be possible to provide a basis for this.

Eligibility criteria:
inclusion criteria: 1. at least 6 weeks after stroke diagnosis 2. upper-extremity (elbow, wrist and finger) spasticity modified ashworth scale (mas) score \> 2 3. ability to stand and walk safely without help or assistance exclusion criteria: 1. improper indication for botulinum toxin a (btxa) injection, for example, myasthenia gravis, eaton-lambert syndrome, amyotrophic lateral sclerosis, and motor neuropathy 2. previous contracture and/or deformity of the upper extremities 3. concurrent peripheral neuropathy and/or myopathy 4. difficulty in participating in the study due to cognitive impairment.
ph ii early bc pre-surgical biologic study

Conditions: Breast Cancer

Summary: a pre-surgery study to assess changes that occur in human breast cancer material and normal skin after a short course of treatment with iressa.


Eligibility criteria:
inclusion criteria: * invasive breast cancer, aged 18 years or older, not more than 28 days from initial diagnosis exclusion criteria: * pregnant or lactating patients, prior or current radiotherapy for breast cancer, known allergy reaction to iressa

Keywords: iressa, gefitinib, breast cancer, surgery
transcranial direct current stimulation in reducing pain in cancer patients with chemotherapy induced peripheral neuropathy

Conditions: Chemotherapy-Induced Peripheral Neuropathy; Malignant Neoplasm

Summary: this early phase i trial studies how well transcranial direct current stimulation works in reducing pain in cancer patients with chemotherapy induced peripheral neuropathy. transcranial direct current stimulation is used for patients with brain injuries such as strokes as well as for mental health issues such as depression and may help to control pain in cancer patients with chemotherapy induced peripheral neuropathy.

primary objectives: i. to evaluate the efficacy of transcranial direct current stimulation (tdcs) in reducing chemotherapy induced painful peripheral neuropathy (cippn). ia. evaluate the change in pain scores ib. assess for changes in other symptoms (i.e insomnia, feeling of well-being, depression and anxiety). secondary objectives: i. to evaluate the following with the treatment of tdcs: ia. assess for changes in using pain medications. ib. assess for changes in functioning (daily activities). ic. assess for changes in quality of life. id. assess for changes in neuropathy. ie. assess overall satisfaction with the tdcs treatment. tertiary objectives: i. to evaluate tdcs treatment related side-effects. outline: patients undergo tdcs once daily (qd) over 20 minutes 5 days each week (monday-friday) for 3 weeks. after completion of study treatment, patients are followed up weekly for 3 weeks and at 4-6 weeks.

Eligibility criteria:
inclusion: * age greater than or equal to 18 years. * able to give a voluntary written consent. * cancer patients with chemotherapy induced peripheral neuropathy of at least 3 months duration.. * pain and/or tingling of at least 4/10 exclusion: * history of seizure * history of migraine headache * history of brain cancer and/or brain metastasis